|
|
News Breaks
|
August 2, 2011
|
| 07:22 EDT |  | MAPP |
| theflyonthewall.com: | MAP Pharmaceuticals' LEVADEX accepted for filing by the FDA | | MAP Pharmaceuticals announced that its New Drug Application, or NDA, for LEVADEX orally inhaled migraine drug for the potential acute treatment of migraine in adults has been accepted for filing by the FDA, with a goal date of March 26, 2012 under the Prescription Drug User Fee Act. In accordance with the Company's collaboration agreement with Allergan the FDA's acceptance for filing of the NDA triggers a milestone payment to MAP Pharmaceuticals of $20M. :theflyonthewall.com |
|
|
News For MAPP From The Last 14 Days Check below for free stories on MAPP the last two weeks.
| Sign up for a free trial to see the rest of the stories you've been missing. |
There are no results for these search parameters.
|
|
|
|
